Results 161 to 170 of about 165,269 (210)

Inhibitors of mammalian target of rapamycin

Drugs of the Future, 2001
The first generation of immunosuppressants such as azathioprine, steroids and anti-lymphocyte-globulins did not provide long-term graft survival in many transplant recipients. After the introduction of calcineurin inhibitors, solid organ transplantation became a standard therapy for many end-stage organ failures and immunosuppressive therapy was later ...
null Klupp, J., null Langrehr, J.M., null Junge, G., null Neuhaus, P.   +3 more
openaire   +1 more source

Inhibitors of the mammalian target of rapamycin

Expert Opinion on Investigational Drugs, 2005
The mammalian target of rapamycin (mTOR) is a downstream protein kinase of the phosphatidylinositol 3'-kinase-Akt signalling pathway. As a result of its position within this pathway and its central role in controlling cellular growth, mTOR is viewed as an important target for anticancer therapeutics development. Currently, the mTOR inhibitor rapamycin (
openaire   +2 more sources

Common toxicities of mammalian target of rapamycin inhibitors

Targeted Oncology, 2011
The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities.
Scott A, Soefje, Anand, Karnad, Andrew J, Brenner   +2 more
openaire   +2 more sources

Role of Mammalian Target of Rapamycin in Atherosclerosis

Current Molecular Medicine, 2018
The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself ...
Z, Cai, Y, He, Y, Chen
openaire   +2 more sources

Dissecting Mammalian Target of Rapamycin to Promote Longevity

Rejuvenation Research, 2012
Treatment with rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) can increase mammalian life span. However, extended treatment with rapamycin results in increased hepatic gluconeogenesis concomitant with glucose and insulin insensitivity through inhibition of mTOR complex 2 (C2).
Andrew R, Mendelsohn, James W, Larrick
openaire   +2 more sources

Mammalian target of rapamycin inhibitors in sarcomas

Current Opinion in Oncology, 2006
Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its ...
openaire   +2 more sources

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors

Transplantation Reviews, 2008
Mammalian target of rapamycin (mTOR) integrates nutrient and hormonal signals involved in cell growth. Development of mTOR inhibitor drugs as therapeutic agents for major human diseases such as obesity, diabetes, atherosclerosis, or cancer will experience an important increase in the next years. The incidence of these diseases is particularly increased
openaire   +2 more sources

Mammalian target of rapamycin signaling in the podocyte

Current Opinion in Nephrology and Hypertension, 2012
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved protein kinase. mTOR forms two distinct functional multiprotein kinase complexes that mutually phosphorylate different substrates and regulate a wide array of essential cellular processes including translation, transcription and autophagy.
Inoki, Ken, Huber, Tobias B.
openaire   +3 more sources

Clinical development of mammalian target of rapamycin inhibitors

Hematology/Oncology Clinics of North America, 2002
Rapamycin and CCI-779 have significant in vitro and in vivo anti-proliferative activity against a broad range of human tumor cell lines, justifying the clinical evaluation of this class of agent in cancer patients. Preliminary results from phase I studies of CCI-779 suggest that the agent is well tolerated and has anti-tumor activity.
openaire   +2 more sources